Cantargia AB (CANTA) AI Stock Analysis

• Market Cap: kr1.24B
• Dividend Yield: N/A
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): 9.8
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.07
• Shares Outstanding: 248,611,650
• 10 Day Avg. Volume: 1,074,033
• 30 Day Avg. Volume: 1,417,172
• PEG Ratio: 0.04
• Price to Book (P/B): 2.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr14.03
• Price Target Upside: 181.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: kr4.50 ▼(-9.64% Downside)

The score is driven primarily by the TTM financial turnaround (profitability and strong cash generation with zero debt), tempered by weak multi-year consistency that questions sustainability. Technicals add support via a clear uptrend and positive momentum, while valuation is helped by a low P/E but lacks dividend support and depends on earnings durability.

Positive Factors

Strong Cash Generation

Strong cash generation supports operational flexibility and reduces reliance on external financing, enhancing financial stability.

Zero Debt

A zero-debt position limits financial risk and provides the company with more strategic options for growth and investment.

Strategic Partnerships

Strategic partnerships can enhance market position and provide access to new technologies and markets, supporting long-term growth.

Negative Factors

Uncertain Revenue Sustainability

The lack of consistent revenue history raises concerns about the sustainability of recent financial improvements and future profitability.

Clinical Trial Results

Unsuccessful trial results can impact the potential for product commercialization and future revenue streams, affecting long-term growth.

Volatile Cash Flow History

Volatile cash flow history highlights uncertainty in cash generation, potentially affecting the company's ability to fund operations and growth.

Cantargia AB Business Overview & Revenue Model

Company Description

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.

How the Company Makes Money

Cantargia AB generates revenue primarily through the development and commercialization of its proprietary antibody therapies. The company seeks to advance its product candidates through clinical trials and obtain regulatory approvals, which can lead to licensing agreements, partnerships, or collaborations with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on clinical and commercial achievements, and royalties on future sales. Additionally, Cantargia may receive funding from grants, research collaborations, or government programs to support its research and development efforts.

Cantargia AB Financial Statement Overview

Summary

Cantargia AB's financial performance is typical of a biotech firm in the development phase, with high operational costs and no revenue. The company has a strong equity base with no debt, but the consistent cash burn presents a sustainability risk unless successful product development leads to revenue generation.

Income Statement

Cantargia AB has reported no revenue over the last several years, indicating no product sales or service income. The company consistently incurs high operating losses, as shown by negative EBIT and net income. There is a lack of any gross profit or revenue growth, highlighting the pre-revenue nature typical of many biotech firms in early development stages.

Balance Sheet

The balance sheet shows a strong equity position with zero debt, reflecting financial prudence in avoiding leverage. However, there has been a significant decline in cash and short-term investments, indicating the burn rate of operations. The equity ratio remains high, suggesting a stable financial structure, but declining equity due to ongoing losses is a concern.

Cash Flow

Operating cash flow is consistently negative, reflecting the cash-intensive nature of biotech R&D activities. Free cash flow is also negative, with no growth prospects in the near term. The company relies heavily on financing activities to sustain operations, but no clear path to cash flow positivity is evident.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	308.69M	0.00	0.00	0.00	0.00	0.00
Gross Profit	306.97M	-3.44M	-3.45M	-3.69M	-3.45M	-3.25M
EBITDA	151.18M	-165.05M	-284.31M	-368.12M	-363.06M	-169.84M
Net Income	139.93M	-161.65M	-280.03M	-371.81M	-366.50M	-173.09M
Balance Sheet
Total Assets	358.89M	170.43M	223.71M	474.80M	600.24M	925.51M
Cash, Cash Equivalents and Short-Term Investments	339.14M	33.04M	194.75M	426.67M	559.39M	903.37M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	61.31M	54.12M	54.97M	85.11M	67.50M	33.58M
Stockholders Equity	297.57M	116.30M	168.74M	389.68M	532.75M	891.93M
Cash Flow
Free Cash Flow	176.04M	-162.75M	-286.66M	-366.00M	-346.83M	-165.39M
Operating Cash Flow	176.50M	-162.75M	-286.66M	-358.92M	-346.44M	-156.39M
Investing Cash Flow	-455.00K	55.00M	182.09M	67.88M	-102.43M	-109.00M
Financing Cash Flow	102.80M	-1.07M	54.68M	223.93M	3.00K	918.51M

Cantargia AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CANTA, the sentiment is Positive. The current price of 4.98 is above the 20-day moving average (MA) of 4.21, above the 50-day MA of 3.77, and above the 200-day MA of 2.50, indicating a bullish trend. The MACD of 0.24 indicates Negative momentum. The RSI at 69.09 is Neutral, neither overbought nor oversold. The STOCH value of 96.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CANTA.

Cantargia AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CANTA	67 Neutral	kr1.24B	9.82	81.19%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCO	50 Neutral	kr1.18B	-3.97	―	―	131.20%	32.28%

Cantargia AB Corporate Events

Cantargia Reports TRIFOUR Study Results on Nadunolimab

Cantargia AB announced that the TRIFOUR study, evaluating nadunolimab in triple-negative breast cancer, showed no difference in median overall survival between the treatment and control groups, both achieving a survival duration of 26 months. Despite the study not meeting its objectives, Cantargia sees potential in nadunolimab for pancreatic cancer, emphasizing the trial’s insights and the drug’s promising efficacy in other cancer types.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

Cantargia AB Releases Interim Report Highlighting Strategic Progress

Cantargia AB has released its interim report for January to September 2025, highlighting its ongoing efforts in developing targeted therapies for critical diseases. The report underscores the company’s strategic advancements and partnerships, which are pivotal in enhancing its market position and providing potential benefits to stakeholders.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

Cantargia AB Announces Nomination Committee for 2026 AGM

Cantargia AB has announced the appointment of its Nomination Committee ahead of the 2026 Annual General Meeting. The committee, representing 13% of Cantargia’s shares, is tasked with proposing key roles and remuneration for the AGM, which will be held on May 21, 2026. This development is part of Cantargia’s ongoing governance and strategic planning, potentially impacting its shareholder engagement and corporate structure.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

Cantargia AB to Release Interim Report and Host Investor Presentation

Cantargia AB announced the release of its interim report for the first nine months of 2025, scheduled for November 19, 2025. The company will hold an audiocast and teleconference on the same day to present the report and engage with investors, analysts, and media. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction following the recent acquisition of CAN10 by Otsuka Pharmaceutical.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

Cantargia AB to Present at Key Investor Conferences

Cantargia AB announced its participation in upcoming investor conferences, including the Stifel 2025 Healthcare Conference in New York City and the DnB Carnegie Nordic Healthcare Conference in Oslo. These events will feature presentations by CEO Hilde Steineger, highlighting the company’s ongoing developments and strategic initiatives. The participation in these conferences may enhance Cantargia’s visibility in the biotechnology sector and provide insights into its future directions, potentially impacting its market positioning and stakeholder engagement.